医药企业新药研发战略优化探析  

ptimization of new drug R&D strategy in pharmaceutical enterprises

作　　者：赵沐子 黄哲[1] ZHAO Mu-zi;HUANG Zhe(Faculty of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016

出　　处：《中国新药杂志》2023年第12期1185-1190,共6页Chinese Journal of New Drugs

摘　　要：新药研发具有技术门槛高、投入大、周期长、涉及学科广、风险高、附加值高的特点,制定并优化新药研发战略对医药企业生存发展意义重大。我国医药企业在创新转型过程中普遍存在新药战略管理缺失的问题。通过分析行业中领先企业案例,探索制定并优化研发战略规划管理及实施管理的方法,以推动企业研发出更多低成本、高质量、具有临床价值和商业价值的新产品,提高我国在创新药领域的影响力和竞争力。New drug RD typically holds the characteristics of high technical barriers of entry,requiring high monetary spending,long cycle of development,multidisciplinary,and carrying high risk and high added value.Formulating and optimizing new drug RD strategy is of great significance to the survival and development of pharmaceutical enterprises.The problem of absence of new drug strategic management is pervasive in the process of innovation and transformation of Chinese pharmaceutical enterprises.Through analyzing the cases of leading enterprises in the industry and exploring the methods to formulate and optimize the management of RD strategic planning and its implementation,the author is dedicated to the benefit of domestic enterprises to promote and develop low-cost,high-quality new products with clinical and commercial value,aiming to improve China's influence and competitiveness in the field of innovative drugs.

关 键 词：医药企业 新药研发 战略 

分 类 号：R95[医药卫生—药学]